A Phase I, Double Blind, Placebo Controlled, Single Ascending Dose Study of Intravenously Administered Ir-CPI to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Healthy Male Volunteers
Latest Information Update: 27 Feb 2023
At a glance
- Drugs Ir-CPI (Primary)
- Indications Thrombosis
- Focus Adverse reactions; First in man
- Sponsors Bioxodes
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 New trial record